New otc weight loss fda approved
adults are obese, and obesity contributes to a number of health conditions, including high blood pressure, type 2 diabetes, and high cholesterol. Belviq should be discontinued if a patient fails to lose 5 percent of their weight after 12 weeks of treatment, as it is unlikely that continued treatment will be successful. Orlistat was initially approved in 1999 as a prescription drug to treat obesity, and remains a prescription drug for obesity at a higher dose than the OTC version. In studies of patients without type 2 diabetes, about 47 percent of patients lost at least 5 percent of their weight compared with 23 percent of patients treated with placebo. Get Consumer Updates by E-mail Consumer Updates RSS Feed. Qsymia is a combination of two FDA-approved drugs: phentermine, an appetite suppressant, and topiramate, used to treat epilepsy and migraines. 7 percent over those taking a placebo. Women who are pregnant or thinking of becoming pregnant should not take either of these medications, Egan says, because weight loss offers no potential benefit to a pregnant woman and can cause fetal harm. Orlistat helps produce weight loss by decreasing the intestinal absorption of fat. Qsymia carries a risk for birth defects (cleft lip with or without cleft palate) in infants exposed during the first trimester of pregnancy. Belviq was tested in three clinical trials that lasted from 52 to 104 weeks and included nearly 8,000 obese and overweight patients. The History More than one-third of U. back to top.
The most common side effect of the product is a change in bowel habits, which may include loose stools. To help obese and overweight Americans who have been unsuccessful in getting their weight under control with diet and exercise, the Food and Drug Administration (FDA) has approved two new medications—the first drugs for long-term weight management that FDA has approved in 13 years. Because of the possible loss of certain nutrients, it is recommended that people using orlistat should also take a multivitamin at bedtime. OTC orlistat will be manufactured by GlaxoSmithKline under the name Alli and is indicated for use in adults ages 18 years and older along with a reduced-calorie, low-fat diet, and exercise program. S. The average weight loss for patients taking Belviq ranged from 3 to 3. The content on this page is provided for reference purposes only. FDA NEWS RELEASE FOR IMMEDIATE RELEASE P07-15 February 7, 2007 Media Inquiries: Kimberly Rawlings, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Approves Orlistat for Over-the-Counter Use The Food and Drug Administration (FDA) today approved orlistat capsules as an over-the-counter (OTC) weight loss aid for overweight adults. Belviq—the trade name for the drug lorcaserin— is a 10 mg tablet taken twice a day that works by activating a part of the brain that controls hunger. This content has not been altered or updated since it was archived. The 60 mg capsule can be taken up to three times a day with each fat-containing meal.
